|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||108.96 - 111.34|
|52-week range||104.50 - 143.90|
|Beta (5Y monthly)||0.13|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||2.80 (2.57%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
FTSE 100 set for record cash returns to investors but dividend forecasts stall.
Astrazeneca (AZN) closed at $55.55 in the latest trading session, marking a +1.29% move from the prior day.
WILMINGTON, Del., October 03, 2022--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.